CD28 and neoplasm: In our pre-treatment analysis, we identified that responders showed a higher frequency of proliferating CD28-expressing CD8 T cells as well as proliferating CD4 conventional T cells, suggestive of ongoing immunity, potentially encompassing anti-tumour immune responses.